CGM Shows Potential for Diagnosing Diabetes in Pregnancy
Early glucose patterns may help identify risk, but evidence doesn't support replacing standard testing.
By
Andrea Surnit
May 5, 2026
Clinical Scorecard: CGM Shows Potential for Diagnosing Diabetes in Pregnancy
At a Glance
Category Detail
Condition Gestational Diabetes Mellitus (GDM) Key Mechanisms Continuous glucose monitoring (CGM) metrics such as mean glucose, glycemic variability, and time in glucose ranges. Target Population Pregnant patients at risk for GDM. Care Setting Obstetric care settings.
Key Highlights
CGM metrics can differentiate patients who develop GDM from those who do not. Higher mean glucose and greater variability observed as early as 13-14 weeks gestation. CGM-derived patterns correlate with adverse neonatal outcomes. Current evidence does not support CGM as a replacement for OGTT. Future diagnostic criteria for CGM may need to be device specific. Guideline-Based Recommendations
Diagnosis
CGM may complement existing screening strategies but is not validated as a standalone diagnostic test. Management
CGM used alongside pharmacotherapy may reduce rates of large-for-gestational-age births. Monitoring & Follow-up
Monitor CGM metrics for glycemic control in pregnant patients. Risks
Adverse neonatal outcomes associated with prolonged time above target glucose levels. Patient & Prescribing Data
Pregnant individuals at risk for gestational diabetes.
Mixed findings on the effectiveness of CGM for managing GDM.
Clinical Best Practices
Utilize CGM data to inform management strategies for GDM. Consider CGM as a supplementary tool rather than a replacement for OGTT. Related Resources & Content
